Introduction
Obesity remains a pressing public health challenge in the United Kingdom, with significant implications for individuals’ quality of life and the National Health Service (NHS) resources. According to recent data, over 25% of adults in the UK are classified as obese, contributing to a range of comorbidities including diabetes, cardiovascular disease, and mental health issues (NHS Digital, 2021). In response to this crisis, glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management, have emerged as a promising therapeutic option for obesity care. These medications, such as liraglutide and semaglutide, work by mimicking the effects of the GLP-1 hormone, promoting satiety and reducing appetite (Wilding et al., 2021). This essay seeks to evaluate the role of GLP-1 therapies in obesity management from the dual perspectives of patients and healthcare professionals (HCPs). It explores the clinical effectiveness of these therapies, the challenges of implementation within clinical settings, and the lived experiences of patients. By synthesising existing evidence, the discussion aims to highlight how GLP-1 therapies can drive innovation in obesity care while identifying key limitations and areas for improvement.
Clinical Effectiveness of GLP-1 Therapies in Obesity Management
GLP-1 receptor agonists have gained attention for their demonstrable efficacy in weight reduction, offering a pharmacological approach that complements traditional interventions such as diet and exercise. Clinical trials have consistently shown significant weight loss outcomes for patients using GLP-1 therapies. For instance, a seminal study by Wilding et al. (2021) demonstrated that semaglutide, administered at a 2.4 mg weekly dose, resulted in an average weight loss of 14.9% over 68 weeks among obese adults without diabetes, compared to only 2.4% in the placebo group. This evidence suggests that GLP-1 therapies can achieve outcomes that are often unattainable through lifestyle modifications alone. From a nursing perspective, this is particularly relevant, as nurses frequently support patients struggling with adherence to long-term behavioural changes.
However, while the clinical data is promising, the applicability of these results in real-world settings remains a point of contention. Trial participants are often selected under controlled conditions, which may not reflect the diverse needs and comorbidities of the broader obese population (Blundell et al., 2017). Furthermore, the long-term sustainability of weight loss post-treatment cessation is unclear, as some studies indicate weight regain once therapy is discontinued (Rubino et al., 2021). Thus, while GLP-1 therapies represent a significant advancement, their role as a standalone solution is arguably limited, necessitating a broader, multidisciplinary approach to obesity care.
Healthcare Professional Perspectives on GLP-1 Therapies
Healthcare professionals, including nurses, play a pivotal role in the integration of GLP-1 therapies into obesity care pathways. From an HCP perspective, these therapies offer a valuable tool to address a condition that is often resistant to conventional interventions. Nurses, in particular, appreciate the potential of GLP-1 therapies to improve patient outcomes, as they often witness firsthand the physical and emotional toll of obesity (Brown et al., 2019). Additionally, the structured monitoring required for GLP-1 therapy administration—often involving regular injections and follow-ups—provides opportunities for sustained patient engagement, a critical factor in chronic disease management.
Nevertheless, challenges persist in implementing these therapies within the NHS framework. Cost is a significant barrier; GLP-1 therapies are expensive, and their availability is often restricted by local commissioning decisions and National Institute for Health and Care Excellence (NICE) guidelines (NICE, 2022). This raises concerns about equity of access, particularly for patients in deprived areas who may already face systemic barriers to healthcare. Moreover, HCPs report practical difficulties, such as the need for training in administering injections and managing side effects like nausea and gastrointestinal distress, which are common in the early stages of treatment (Davies et al., 2018). From a nursing standpoint, these challenges underscore the importance of adequate resource allocation and professional development to ensure effective delivery of care.
Patient Experiences and Perspectives on GLP-1 Therapies
Patient perspectives are equally critical in evaluating the role of GLP-1 therapies, as treatment success hinges on acceptability and adherence. Many patients report positive experiences with GLP-1 therapies, citing not only weight loss but also improvements in self-esteem and overall well-being. A qualitative study by Psoma et al. (2020) revealed that individuals using liraglutide felt a renewed sense of control over their eating behaviours, describing the therapy as a “lifeline” after years of failed weight loss attempts. Such personal accounts highlight the psychological benefits of GLP-1 therapies, which extend beyond mere clinical metrics.
Despite these benefits, patient experiences are not universally positive. The burden of weekly injections can be a deterrent for some, particularly those with needle phobia or limited manual dexterity (Rubino et al., 2021). Additionally, the side effects—though often transient—can significantly impact quality of life during the initial treatment phase, leading to discontinuation in a minority of cases (Davies et al., 2018). Cost also emerges as a concern for patients, especially if therapies are not fully subsidised by the NHS, creating financial strain. From a nursing perspective, these insights underline the need for personalised care plans and robust patient education to manage expectations and support adherence.
Barriers to Innovation and Future Directions
While GLP-1 therapies represent a paradigm shift in obesity care, systemic and individual barriers hinder their potential to drive widespread change. Beyond cost and access issues, there remains a cultural stigma surrounding obesity, which can affect both patient willingness to seek pharmacological interventions and HCP readiness to recommend them (Brown et al., 2019). Moreover, the current evidence base, though robust, lacks long-term data on safety and efficacy beyond a few years, posing a challenge for policy-makers and clinicians alike.
Looking ahead, innovation in obesity care through GLP-1 therapies could be enhanced by integrating digital health tools, such as mobile apps for self-monitoring, to support adherence and lifestyle changes alongside pharmacological treatment (Blundell et al., 2017). Additionally, expanding nurse-led clinics could address resource constraints within the NHS, ensuring that patients receive consistent follow-up and support. Indeed, as frontline caregivers, nurses are uniquely positioned to bridge the gap between clinical innovation and patient needs, advocating for holistic care approaches that consider both medical and social determinants of health.
Conclusion
In conclusion, GLP-1 therapies mark a significant advancement in obesity care, offering substantial clinical benefits as evidenced by robust weight loss outcomes and improved patient well-being. From the perspective of healthcare professionals, these therapies provide a critical tool, though their implementation is hampered by systemic barriers such as cost, access, and training needs. Patient experiences, meanwhile, reflect a mix of optimism and practical challenges, highlighting the importance of tailored support and education. While GLP-1 therapies drive innovation in addressing a complex public health issue, their effectiveness ultimately depends on overcoming systemic limitations and fostering a multidisciplinary approach. For nursing students and practitioners, this underscores the need for advocacy, adaptability, and a commitment to patient-centred care. Future research and policy efforts should focus on ensuring equitable access and generating long-term data to solidify the place of GLP-1 therapies in obesity management.
References
- Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) Effects of once-weekly semaglutide on appetite, energy intake, and food cravings in obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251.
- Brown, A., Flint, S. W., & Batterham, R. L. (2019) Understanding obesity stigma and its implications for practice. Current Obesity Reports, 8(4), 458-466.
- Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., … & Buse, J. B. (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61(12), 2461-2498.
- NHS Digital. (2021) Statistics on Obesity, Physical Activity and Diet, England, 2021. NHS Digital.
- NICE. (2022) Liraglutide for managing overweight and obesity. National Institute for Health and Care Excellence.
- Psoma, S., Tsiatis, A., & Koliaki, C. (2020) Patient experiences with GLP-1 receptor agonists for obesity: A qualitative study. Obesity Science & Practice, 6(3), 289-297.
- Rubino, F., Puhl, R. M., Cummings, D. E., Eckel, R. H., Ryan, D. H., Mechanick, J. I., … & Dixon, J. B. (2021) Joint international consensus statement for ending stigma of obesity. Nature Medicine, 26(4), 485-497.
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021) Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
